A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them and do not have an alternative drug to overcome the problem. The levels of β-cate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang-Kyu, Cho, Yong-Hee, Cha, Pu-Hyeon, Yoon, Jeong-Soo, Ro, Eun Ji, Jeong, Woo-Jeong, Park, Jieun, Kim, Hyuntae, Il Kim, Tae, Min, Do Sik, Han, Gyoonhee, Choi, Kang-Yell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244225/
https://www.ncbi.nlm.nih.gov/pubmed/30459318
http://dx.doi.org/10.1038/s12276-018-0182-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244225/
https://www.ncbi.nlm.nih.gov/pubmed/30459318
http://dx.doi.org/10.1038/s12276-018-0182-2

Ejemplares similares